Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Chemed Corporation’s (NYSE: CHE) SEC filings, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Chemed is a Delaware-incorporated holding company headquartered in Cincinnati, Ohio, operating VITAS Healthcare and Roto-Rooter as wholly owned subsidiaries.
For investors analyzing Chemed’s hospice operations, filings and related exhibits can offer detail on VITAS Healthcare’s net patient revenue, average daily census, admissions, and the impact of Medicare reimbursement rates and Medicare Cap billing limitations. Management’s discussion of these topics in earnings releases, which are often furnished as exhibits to Form 8-K, helps explain how regulatory and reimbursement factors influence segment performance.
Filings also shed light on Roto-Rooter’s plumbing, drain cleaning, water restoration, and water cleanup services. Segment disclosures in attached earnings releases describe revenue trends across commercial and residential customers, gross margins, selling, general and administrative expenses, and adjusted EBITDA margins. These details help readers understand how demand for plumbing and drain cleaning services affects Chemed’s consolidated results.
Chemed’s SEC filings may address capital structure and capital allocation, including its Amended and Restated Credit Agreement, share repurchase authorizations, and long-running dividend program. They can also disclose material events such as updates to earnings guidance, executive leadership changes, or other significant corporate developments.
On this page, AI-powered tools summarize lengthy filings and attached press releases, highlighting items such as quarterly earnings (often reported via Form 8-K), non-GAAP measures like EBITDA and Adjusted Diluted EPS, and regulatory or reimbursement disclosures relevant to VITAS and Roto-Rooter. Users can also review insider- and management-related information when it appears in current reports or other SEC documents.
Chemed Corporation (NYSE: CHE) filed a Form 8-K on June 27, 2025 to furnish a Regulation FD disclosure.
- Material event: The Company issued a press release (Exhibit 99) stating it now expects second-quarter 2025 earnings to be lower than previously anticipated and is reducing its full-year 2025 earnings guidance.
- The filing does not include specific dollar amounts, revised EPS figures or updated revenue ranges; only the direction of the change is disclosed.
- No other operational changes, financings, or acquisitions were reported in the filing.
- The press release itself is furnished, not filed, preserving safe-harbor protections for forward-looking statements.
Because the Company is signalling weaker performance and a downward revision to outlook, the disclosure is materially negative for investors, implying potential pressure on near-term financial results and valuation multiples. Investors will need to review the full press release and forthcoming Q2 results to quantify the impact.